Acne vulgaris causes cosmetic impairment. User-friendly anti-acne monotherapy with adapalene has activity against the acne
pathophysiology, with very minimal adverse effects. Retinoids, like adapalene, are comedolytic and anti-inflammatory. This study was
conducted as a pharmacovigilance study of topical acne monotherapy with 0.1% adapalene, and a molecular analytical review of
adapalene in evidence-based dermatopharmacological treatment. A prospective, open- labelled study was done, on 75 patients, with
mild to moderate acne. Patients applied 0.1% adapalene topical monotherapy, once daily in the evening, over affected areas on the
face, and left overnight. Efficacy was measured by percentage reduction in non-inflammatory, inflammatory and total lesion counts
on 0, 15, 30, 60 and 90 days; and severity of lesions was assessed by Investigator’s Global Evaluation Scale and the occurrence of
adverse effects like erythyma, dryness, scaling, burning and pruritus, were assessed by the Local Irritation Scale, among the patients
receiving the monotherapy. An analytical review of the molecular pharmacology of adapalene in evidence-based
dermatopharmacological treatment was thoroughly performed. The patients showed highly significant reduction in total lesion
counts from baseline. No serious adverse effects were observed; and the observations were statistically non-significant. The
molecular analytical review described significantly effective evidence-based dermatopharmacological response mechanisms of
adapalene therapeutics. Topical 0.1% adapalene monotherapy was effective and safe, with significant evidence-based molecular
dermatopharmacological efficacy.
A Pharmacovigilance Study of Topical Acne Monotherapy with 0.1% Adapalene, and A Molecular Analytical Review of Adapalene in Evidence-Based Dermatopharmacological Treatment
